公开(公告)号：US20100331382A1

公开(公告)日：2010-12-30

申请号：US12840505

申请日：2010-07-21

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

IPC: A61K31/4188 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US20100324126A1

公开(公告)日：2010-12-23

申请号：US12838795

申请日：2010-07-19

Applicant: Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan ,  Varda Sandweiss ,  Sydney Ugwu

Inventor： Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan ,  Varda Sandweiss ,  Sydney Ugwu

IPC: A61K31/7088 ,  A61K31/70

CPC classification number: A61K31/7028 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/70 ,  A61K31/704 ,  A61K38/212 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K48/00 ,  A61K48/0008 ,  C07J41/0061 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10351

Abstract: Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.

Abstract translation: 公开了含有可用于治疗癌症的药剂的含水和非水溶液制剂。

公开(公告)号：US20120053219A1

公开(公告)日：2012-03-01

申请号：US13290251

申请日：2011-11-07

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

IPC: A61K31/4188 ,  A61P35/02 ,  A61P35/00 ,  A61K47/16 ,  A61P31/10

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US08076335B2

公开(公告)日：2011-12-13

申请号：US12840505

申请日：2010-07-21

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Lenore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Lenore C. Witchey-Lakshmanan

IPC: A61K31/53 ,  A61K31/415 ,  A61K31/16

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US07674790B2

公开(公告)日：2010-03-09

申请号：US11332721

申请日：2006-01-13

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

IPC: A61K31/53 ,  A61K31/415 ,  A61K31/16

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US20060009469A1

公开(公告)日：2006-01-12

申请号：US11140294

申请日：2005-05-27

Applicant: Leonore Witchey-Lakshmanan ,  Sydney Ugwu ,  Varda Sandweiss ,  Catherine Hardalo ,  Roberta Hare ,  Gopal Krishna ,  Zaiqi Wang ,  Marco Taglietto

Inventor： Leonore Witchey-Lakshmanan ,  Sydney Ugwu ,  Varda Sandweiss ,  Catherine Hardalo ,  Roberta Hare ,  Gopal Krishna ,  Zaiqi Wang ,  Marco Taglietto

IPC: A61K31/496

CPC classification number: A61K9/0019 ,  A61K31/137 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7048 ,  A61K45/06 ,  A61K47/24 ,  A61K47/26 ,  Y02A50/409 ,  Y02A50/414 ,  A61K2300/00

Abstract: The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient posaconazole in an injectable suspension that is stable when subjected to terminal steam sterilization.

Abstract translation: 本发明提供了可用于治疗感染的制剂，特别是在经受终端蒸汽灭菌时稳定的可注射悬浮液中包含活性药物成分泊沙康唑的制剂。

公开(公告)号：US20060160823A1

公开(公告)日：2006-07-20

申请号：US11300677

申请日：2005-12-14

Applicant: Leonore Witchey-Lakshmanan ,  Sydney Ugwu ,  Varda Sandweiss ,  Catherine Hardalo ,  Roberta Hare ,  Gopal Krishna ,  Zaiqi Wang ,  Marco Taglietti

Inventor： Leonore Witchey-Lakshmanan ,  Sydney Ugwu ,  Varda Sandweiss ,  Catherine Hardalo ,  Roberta Hare ,  Gopal Krishna ,  Zaiqi Wang ,  Marco Taglietti

IPC: A61K31/496

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/513 ,  A61K31/7048 ,  A61K45/06 ,  A61K47/24 ,  A61K47/26 ,  Y02A50/409 ,  Y02A50/414 ,  A61K2300/00

Abstract: The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics, such as those displayed below.

Abstract translation: 本发明提供了可用于治疗感染的制剂，特别是包含活性药物成分泊沙康唑在经受终末灭菌时稳定的颗粒的可注射悬浮液中的制剂。 发现优选的中值粒度在1.5和3.0微米之间导致优异的药代动力学特征，例如下面显示的那些。

公开(公告)号：US20060122163A1

公开(公告)日：2006-06-08

申请号：US11332721

申请日：2006-01-13

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter Ihnat ,  Leonore Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter Ihnat ,  Leonore Witchey-Lakshmanan

IPC: A61K31/4188 ,  A61K31/4172 ,  A61K31/198

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US06987108B2

公开(公告)日：2006-01-17

申请号：US10371808

申请日：2003-02-21

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Leonore C. Witchey-Lakshmanan

IPC: A61K31/16 ,  A61K31/53 ,  A61K31/415

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。

公开(公告)号：US20140088166A1

公开(公告)日：2014-03-27

申请号：US14093712

申请日：2013-12-02

Applicant: Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Lenore C. Witchey-Lakshmanan

Inventor： Sydney Ugwu ,  Vinay Radhakrishnan ,  Peter M. Ihnat ,  Lenore C. Witchey-Lakshmanan

IPC: A61K31/495 ,  A61K47/18

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/395 ,  A61K31/522 ,  A61K31/66 ,  A61K31/704 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract translation: 在其几个实施方案中，本发明公开了一种药物制剂，其包含至少一种抗肿瘤剂或其药学上可接受的盐，以及至少一种溶解增强剂，其足以在至少一种含水稀释剂中基本上溶解所述至少一种抗肿瘤剂，其中所述 溶解促进剂是尿素，L-组氨酸，L-苏氨酸，L-天冬酰胺，L-丝氨酸，L-谷氨酰胺或其混合物; 包含所述药物制剂的冻干粉末及其制品。